1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Title

The fungal-specific Hda2 and Hda3 proteins regulate morphological switches
in the human fungal pathogen *Candida albicans*.

Running title:

Hda2 and Hda3 control *C. albicans* morphogenesis

Misty R. Peterson^a, Robert Jordan Price^a, Sarah Gourlay^a, Alisha May^{a*}, Jennifer
Tullet^a and Alessia Buscaino^{a#}

^a: Kent Fungal Group, School of Biosciences, University of Kent, Canterbury, United
Kingdom

#Address correspondence to Alessia Buscaino, A.Buscaino@kent.ac.uk

*: Present address: Department of Life Sciences, Imperial College London, South
Kensington Campus, London, SW7 2AZ

Word Count Main Text: 3902

Word Count Material and Methods: 1880

ABSTRACT

The human fungal pathogen *Candida albicans* is responsible for millions of infections annually. Due to the few available anti-fungal drugs and the increasing incidence of drug resistance, the number of *C. albicans* infections is dramatically increasing. Morphological switches, such as the white-opaque switch and the yeast-hyphae switch, are key for the development of *C. albicans* pathogenic traits. Lysine deacetylases are emerging as important regulators of morphological switches. Yet, targeting lysine deacetylases for drug development is problematic due to the high homology between the fungal and human proteins that could result in toxicity. Here we provide evidence that the fungal specific proteins Hda2 and Hda3 interact with the lysine deacetylase Hda1. By combining phenotypic analyses with genome-wide transcriptome analyses, we demonstrate that Hda2 and Hda3 control *C. albicans* morphological switches. Under nutrient-rich conditions, deletion of *HDA2* or *HDA3* leads to moderate overexpression of the master regulator of white-opaque switching *WOR1* and increase switching frequency. Under hyphae inducing conditions, deletion of *HDA2* and *HDA3* block hyphae development. However, deletion of *HDA2* and *HDA3* does not affect hyphae-formation and virulence *in vivo*. We propose that Hda2 and Hda3 are good targets for the development of anti-fungal drugs to be used in combination therapy.

KEYWORDS

KDACs, *Candida albicans*, morphological switches, white and opaque switch, yeast to hyphae switch

INTRODUCTION

Fungal pathogens are a leading cause of human mortality causing over 1.5 million deaths per year (1). *C. albicans* is a commensal organism that colonises the mouth, gastrointestinal and reproductive tract of healthy individuals without causing any harm. Still, *Candida albicans* is also the most common human fungal pathogen and the principal causal agent of mycotic death (2). This is because, in immune-compromised patients, *C. albicans* can invade vital organs and cause serious, life-threatening systemic infections associated with a mortality rate up to 70 % (2). The ability to transition between different morphological forms in response to changing environments is a key virulence trait in *C. albicans*.

For example, *C. albicans* cells can reversibly switch between white and opaque forms (3). White and opaque cells are genetically identical, yet they differ in cellular morphology, colony shape, gene expression profile and mating behaviour (4). In addition, white cells are more virulent in a murine model of systemic infection (5, 6) whereas opaque cells preferentially colonise the skin (7). White-opaque switching is under the control of the master regulator Wor1, a transcription factor whose expression is necessary and sufficient for opaque cell formation (8–11). Stochastic increases in Wor1 levels drives the transition from the white to the opaque phase. Furthermore, Wor1 expression produces a direct positive feedback loop by binding its own promoter and turning on its own expression (8, 9, 11). Switching is also regulated by the mating type locus as opaque formation occurs predominantly in a or α cells (12).

C. albicans virulence also depends on its ability to convert between yeast and hyphal morphology: yeast cells are critical for colonisation, early infection and dissemination, while hyphal growth is responsible for tissue invasion and chronic

infections (13). Hyphal morphogenesis is coupled with virulence, as several of the genes, that are specifically expressed in hyphae, encode virulence factors (14–17). Hyphal morphogenesis is a complex and highly orchestrated process, and *C. albicans* uses multiple redundant pathways to integrate host signals and promote hyphae development. Indeed, *C. albicans* filamentation can be induced by many environmental cues such mammalian serum, body temperature, hypoxia and CO₂ concentration which reflects the variety of signals sensed by the fungus in the different microenvironments encountered in the host. In yeast cells, hyphae morphogenesis is inhibited by the DNA-binding repressor Nrg1 that, together with Tup1, blocks expression of a subset of filament-specific genes (18). Upon hyphal induction, filamentous growth is promoted by Efg1 and Flo8, two transcription regulators essential for hyphal development and virulence [14–16]. During the initiation phase of hyphae morphogenesis, Nrg1-mediated repression is cleared via *NRG1* transcriptional repression and Nrg1 protein degradation. During hyphae maintenance, chromatin remodelling of hyphae promoters prevents Nrg1 binding despite its increased protein levels (19).

Due to the close evolutionary relationship between fungi and the human host, effective treatment for *C. albicans* infections is hindered by the limited number of sufficiently divergent potential drug targets. There are only three classes of antifungal drugs effective for the treatment of systemic fungal infections and their clinical utility is limited by the rapid emergence of drug resistance (1, 20). Hence, there is an immediate and urgent need to develop alternative treatments. A potential strategy is to target *C. albicans* morphological plasticity.

Lysine deacetylases (KDACs, also known as HDACs) act as global regulators of gene expression by catalysing the removal of acetyl functional groups from the lysine

residues of histones and non-histone proteins (21). KDACs can favour transcriptional repression by deacetylating lysine residues on histone tails allowing chromatin compaction and/or preventing binding of bromodomain-containing transcriptional activators (21). KDACs can also activate transcription by deacetylation of non-histone proteins (22). As a consequence, deletion or inhibition of KDACs often results in the upregulation and downregulation of an approximately equivalent number of genes (23). KDACs are highly conserved across eukaryotes and can be phylogenetically divided into three main classes: the Rpd3 and Hos2-like (class I) enzymes, the Hda1-like (class II) enzymes and the Sir2-like (class III) enzymes. The class I and class II enzymes are related, sharing a conserved central enzymatic domain. The class III enzymes are nicotinamide adenine dinucleotide (NAD) dependent. KDACs lack intrinsic DNA-binding activity and are recruited to target genes via incorporation into large multiprotein complexes or direct association with transcriptional activators and repressors (24).

In *C. albicans*, the lysine deacetylase Hda1 (class II) is an important regulator of morphological switches. Hda1 controls white-opaque switching as deletion of the *HDA1* gene increases switching rates from white to opaque (25, 26). In response to serum, N-acetylglucosamine or nutrient limitation, Hda1 also controls the yeast to hyphae switch by deacetylating Yng2, a component of the histone acetyltransferase NuA4 complex, blocking maintenance of hyphal growth (19). However, the Hda1 pathway is not required for hyphae elongation in hypoxia or in the presence of elevated CO₂ because of the presence of redundant pathways (27, 28). As a result, the Hda1-mediated hyphae maintenance pathway contributes, but it is not absolutely required, for virulence *in vivo* (27). These results suggest that Hda1 is a good target for antifungal drugs development to be used in combination therapies.

KDACs are promising druggable targets: one KDAC inhibitor is currently used for cancer treatment and several other KDAC inhibitors are in clinical trials (29, 30). However effective targeting of Hda1 for anti-fungal drug development is impaired by the high sequence similarities between Hda1 and its human orthologs and consequently a likeliness for high toxicity.

In *Saccharomyces cerevisiae*, Hda1 assembles with two non-catalytic subunits, Hda2 and Hda3, essential for Hda1 deacetylation activity both *in vivo* and *in vitro* (31). Interestingly, no metazoan homologous of Hda2 and Hda3 have been identified. Hda2 and Hda3 are similar in sequence and share a similar protein organisation with an N-terminal DNA binding domain (DBD) and a C-terminal coil-coil domain (CCD). The DBD domain, similar in structure to the helicase domain of the SWI-SNF chromatin remodellers, is sufficient to bind DNA *in vitro*. The CCD domains act as a scaffold for the assembly of the Hda1 complex (32).

Here for the first time, we analyse the role of *C. albicans* Hda2 and Hda3. We demonstrate that the Hda1 complex is conserved in *C. albicans* as Hda2 and Hda3 interact with Hda1 *in vivo*. Our analyses demonstrated that, in yeast-inducing conditions, deletion of *HDA2* and *HDA3* leads to transcriptional upregulation of *WOR1* and that Hda2 and Hda3 inhibit white and opaque switching. In contrast, under hyphae-inducing conditions, Hda2 and Hda3 regulate the yeast to hyphae switch. This functional rewiring is linked to a reduced expression of components of the Hda1 complex. Our study demonstrates that Hda2 and Hda3 control key morphological switches in *C. albicans*. Therefore, we propose that Hda2 and Hda3 are attractive targets for the development of novel antifungal drugs.

RESULTS

The Hda1 complex is conserved in *C. albicans*

S. cerevisiae Hda2 and Hda3 are critical components of the Hda1 complex as they are required for the Hda1-mediated histone deacetylation activity (31). BLAST analyses reveal that the *C. albicans* genome contains two genes encoding proteins with homology to *S. cerevisiae* Hda2 (C3_03670W) and Hda3 (CR_09490W_A). Structural alignments predict that Hda2 and Hda3 have a similar protein organisation with an N-terminal DNA binding domain (DBD) and a C-terminal coil-coil domain (CCD) (Fig 1A and 1B). To explore the potential functional relationship between *C. albicans* Hda2, Hda3 and Hda1, we assessed whether we could detect a physical interaction between these proteins. To this end, we generated strains expressing at the endogenous locus an epitope-tagged Hda1 protein (Hda1-HA) together with either Hda2-GFP or Hda3-GFP. Western analyses show that the Hda1-HA and Hda2-GFP tagged proteins are expressed at high levels while we could not detect Hda3-GFP in whole cell extract indicating that the protein is expressed at low levels (Fig 1C). Immuno-precipitation (Ip) of Hda1-HA with a highly specific anti-HA antibody demonstrates that Hda2 strongly interacts with Hda1. We could also detect an interaction between Hda1 and Hda3, despite the low level of expression of Hda3 (Fig 1C). Thus, Hda2 and Hda3 physically interact with Hda1. To delineate the function of *C. albicans* Hda2 and Hda3, we generated homozygous deletions mutants for *HDA2* (*hda2* Δ/Δ) and *HDA3* (*hda3* Δ/Δ) genes using a recyclable Clox system (Fig 1D) (33). The Clox system allows for the generation of a homozygous deletion mutant lacking any marker genes and therefore genetically identical to the parental strain except for the deleted gene. This allows for the direct comparison of phenotypes between mutant and parental strains. Growth analyses reveal that Hda2 and Hda3 are not required for survival and fitness as the *hda2* Δ/Δ and *hda3* Δ/Δ

strains grow similarly to the wild-type (WT) control both on solid and in liquid media (Fig 1E and 1F). Therefore, *C. albicans* Hda2 and Hda3 are *bonafide* components of the Hda1 complex that are not required for cell fitness and survival under optimal growth conditions.

Global gene expression changes in the absence of Hda2 and Hda3

To gain insights about the function of Hda2 and Hda3 in conditions stimulating yeast growth, we analysed changes in gene expression by strand-specific RNA-sequencing (RNA-seq) upon deletion of the *HDA2* and *HDA3* genes. As a comparison, we also performed RNA-seq on strains with the *HDA1* gene deleted. Deletion of *HDA2* results in 577 genes significantly differentially regulated (348 upregulated and 229 downregulated, $q < 0.05$; Dataset S1). These gene expression changes are highly similar to the ones observed in *hda1* Δ/Δ (Pearson correlation coefficient $r = 0.7$, Dataset S1) (Fig 2A). Deletion of the *HDA3* gene has a less profound effect on gene expression as only 78 genes are significantly differentially expressed (45 upregulated and 33 downregulated, $q < 0.05$; Dataset S1). Despite this difference, changes in *hda3* Δ/Δ cells correlate with *hda1* Δ/Δ and *hda2* Δ/Δ gene expression changes (Pearson correlation coefficient $r = 0.66$ and 0.46 , respectively) (Fig 2A).

To reveal the cellular pathways regulated by Hda2 and Hda3 in *C. albicans*, we performed Gene Set Enrichment Analysis (GSEA) of the RNA-seq datasets (34). To this end, transcript profiles of *hda2* Δ/Δ or *hda3* Δ/Δ isolates were ranked according to their differential expression and this list was compared to gene sets identified in other experimental analyses (35) and (Sellam et al, personal communications). This

allows the identification of statistically significant gene sets enriched in the top (up-regulated) or the bottom (down-regulated genes) of the ranked list (34). The network of similar gene sets was visualized using Cytoscape where nodes represent gene sets, and lines connect nodes sharing a significant number of genes (36). GSEA detected enrichment for rRNA and ribosome biogenesis genes and genes involved in transport (Fig 2B). Enrichment was also found in gene sets important for virulence-promoting function in *C. albicans*. This includes genes differentially expressed during *C. albicans*-host interactions with mouse macrophages and in response to drugs (Fig 2C).

Modulation of several gene sets enriched in *hda2* Δ/Δ and/or *hda3* Δ/Δ mutants, for example, down-regulation of genes required for protein synthesis, are part of stress response in *C. albicans* (37). Accordingly, we subjected the *hda2* Δ/Δ and *hda3* Δ/Δ mutants to a phenotypic analysis by applying a set of different stress conditions (38). For most conditions, we did not observe any difference between the WT and the mutant strains. However, lack of Hda2 or Hda3 leads to sensitivity to copper, sodium chloride and sodium nitroprusside (SNP) with salicylhydroxamic acid (SHAM). Strains mutant in these proteins also show resistance to rapamycin (Fig 3) indicating a role for Hda2 and Hda3 in specific stress responses.

Hda2 and Hda3 inhibit white-opaque switching

The GSEA analysis identifies white-opaque switching as a process potentially regulated by Hda2 and Hda3 as genes upregulated in the opaque state are also upregulated upon deletion of *HDA2* and *HDA3* (Fig 4A and 4B). Wor1 is the master regulator of white-opaque phenotypic switching and a stochastic increase in Wor1 levels drives the transition from the white to the opaque phase (8, 9, 11). Therefore,

we asked whether *WOR1* expression levels were increased in *hda2* Δ/Δ and *hda3* Δ/Δ isolates compared to WT cells.

The RNA sequencing analysis demonstrates that deletion of *HDA2* or *HDA3* leads to transcriptional upregulation of *WOR1* (Fig 4C). This result suggests that, in WT cells, Hda2 and Hda3 repress *WOR1* transcription and inhibit white-opaque switching. To test this hypothesis, we generated *MTL a/a* homozygous *hda2* Δ/Δ and *hda3* Δ/Δ mutants and measured the frequency of white to opaque conversion using quantitative switching assays. Briefly, cells were plated on Phloxine B plates and the frequency of opaque colonies or colonies containing at least one opaque sector was scored. This analysis demonstrates that deletion of both *HDA2* and *HDA3* increases the frequency of white-opaque switching (Fig 4D). Thus, Hda2 and Hda3 control white-opaque switching, a process that is linked to *WOR1* overexpression.

Hda2 and Hda3 contribute to filamentous growth but not virulence

To investigate the role of Hda2 and Hda3 under hyphae-inducing conditions, we performed RNA-seq analyses of WT, *hda2* Δ/Δ and *hda3* Δ/Δ strains grown in RPMI, a medium which mimics human physiological conditions and therefore strongly induces hyphal growth. As a control, RNA-seq analyses were also performed in *hda1* Δ/Δ strain. GSEA analysis of the gene expression changes of WT cells grown in yeast-inducing conditions (YPD) and hyphae-inducing conditions (RPMI) confirmed the validity of our experimental approach as genes reported to be upregulated in hyphae compared to yeast are less expressed in YPD compared to RPMI while genes with a yeast-specific expression are expressed at higher levels in YPD than RPMI (Fig 5A).

In hyphae-inducing conditions, deletions of *HDA2* and *HDA3* genes result in 350 and 484 significantly differentially expressed genes, respectively ($q < 0.05$; Dataset S1). Gene expression changes in *hda2* Δ/Δ and *hda3* Δ/Δ correlate with gene expression changes observed in *hda1* Δ/Δ although less profoundly than in yeast-inducing conditions (Pearson correlation coefficient, $r = 0.55$ and 0.38 , respectively; Fig 5B). The RNA-seq analysis reveals that filamentation is the major pathway misexpressed in the deletion mutants as hyphae-responsive genes are differentially expressed in *hda2* Δ/Δ and *hda3* Δ/Δ isolates compared to WT cells (Fig 5C). qRT-PCR analyses of two hyphal growth markers, *HWP1* and *ALS3*, confirmed the RNA-seq results as, in hyphae inducing conditions, expression of *HWP1* and *ALS3* is downregulated in *hda2* Δ/Δ and *hda3* Δ/Δ but not in WT cells (Fig 5D). Collectively, our results suggest that Hda2 and Hda3 are important for hyphal growth. To test this hypothesis, we assessed the morphology of WT, *hda2* Δ/Δ and *hda3* Δ/Δ strains upon growth in two different hyphae-inducing media (RPMI and Spider). While WT cells form hyphae efficiently, hyphal growth is defective in *hda2* Δ/Δ and *hda3* Δ/Δ cells on both solid and in liquid media (Fig 6A and B). This phenotype was rescued by reintroduction of the *HDA3* gene (Fig 6C). Therefore, Hda2 and Hda3 are important regulators of the yeast to hyphae switch. To test whether the hyphae-defective phenotype observed in *hda2* Δ/Δ and *hda3* Δ/Δ isolates is sufficient to impair hyphal growth *in vivo*, we performed killing assays using the nematode *Caenorhabditis elegans* as an infection system (39, 40). These analyses revealed no differences in hyphae formation or percentage of killing between WT, *hda2* Δ/Δ and *hda3* Δ/Δ strains (Fig 6D). Therefore, although Hda2 and Hda3 are critical for hyphae-formation in specific media, additional redundant

pathways can compensate for the lack of Hda2 and Hda3 in a more complex *in vivo* situation.

Stability of Hda1 protein is regulated by environmental changes

Comparison of the gene expression profiles in yeast-promoting conditions (YPD 30 °C) and hyphae-promoting conditions (RPMI 37 °C) reveals that deletion of *HDA1* leads to different transcriptional changes in different environments (Fig 7A). In yeast inducing conditions, 2046 genes are significantly differentially expressed upon deletion of Hda1 compared to WT cells, suggesting that Hda1 acts as a global regulator of gene expression (Fig 7A and Dataset S1). In contrast, in hyphae inducing conditions, 507 genes are significantly differentially expressed with hyphal growth being one of the major pathways that is altered (Fig 7B and Dataset S1). These results suggest that Hda1 function is rewired during the yeast to hyphae switch. We hypothesise that this change in function could be due to a differential gene expression profile of *HDA1* in yeast compared to hyphae. While analysis of the RNA-seq dataset reveals that *HDA1*, *HDA2* and *HDA3* transcription levels are similar across these two conditions, Western analyses clearly demonstrate that levels of Hda1 and Hda3 proteins, but not Hda2, are lower in hyphal cells compared to yeast cells (Fig 7C). Therefore, the functional rewiring of the Hda1 complex upon an environmental change is linked to a reduced expression of this subunit.

DISCUSSION

The role of the Hda1 complex in regulating morphological switches in *C. albicans*

Results presented in this study show that the fungal-specific proteins Hda2 and Hda3 are important regulators of morphological switches in *C. albicans*. We propose

that this regulation is mediated via the Hda1 complex. This hypothesis is supported by our observation that Hda1, Hda2 and Hda3 physically interact and by the published results demonstrating that Hda1 controls both the white-opaque and the yeast-hyphae morphological switches (19, 25, 26). Based on the data presented here, it is possible that Hda2 and Hda3 control the activity of the Hda1 complex by different non-mutually exclusive mechanisms. First, Hda2 and Hda3 could mediate Hda1 recruitment to target sites regulating their chromatin acetylation state and their transcriptional activity. Indeed, in *S. cerevisiae*, Hda2 and Hda3 DNA-binding domains are sufficient to bind DNA *in vitro* (32). The structural alignment presented in this study demonstrates that, similar to *S. cerevisiae*, *C. albicans* Hda2 and Hda3 contain a DNA binding domains with structure resembling the helicase fold found in the SWI2/SNF2-type chromatin-remodeling ATPase (32). We hypothesise that Hda2 and Hda3 could target Hda1 to key genomic locations leading to transcriptional downregulation of associated genes. In support of this hypothesis, we have found that *WOR1*, the master regulator of white-opaque switching, is moderately upregulated in cells deleted for *HDA2* and *HDA3* genes. A similar upregulation is observed in *hda1* Δ/Δ isolates. We propose that this upregulation is sufficient to activate the Wor1 positive feedback loop promoting white-opaque switching. Indeed, *hda2* Δ/Δ and *hda3* Δ/Δ cells undergo white-opaque switching more frequently than WT cells.

Alternatively, interactions between Hda1, Hda2 and Hda3 may induce a conformational change promoting Hda1 deacetylase activity. In support of this hypothesis, it has been established that the *in vitro* catalytic activity of *S. cerevisiae* Hda1 depends on Hda2 and Hda3 (31). This regulation could be critical for controlling deacetylation of non-histone substrates. For example, *C. albicans* Hda1

controls the yeast to hyphae switch by deacetylating a non-histone substrate, the NuA4 component Yng2 (19). We hypothesise that interaction between Hda1, Hda2 and Hda3 causes a conformational change in Hda1 allowing deacetylation of Yng2. Chromatin modifiers are ideal sensors of changing environments as they can respond to external stimuli by rapidly and reversibly changing the transcriptional state of many genes simultaneously. Our results indicate that the activity of the Hda1 complex is rewired in different environmental conditions. While in yeast cells, Hda1 acts as a globular regulator of gene expression, in hyphae-inducing conditions Hda1 function is dedicated to the yeast-hyphae switch. This functional rewiring is accompanied by changes in the protein levels of Hda1 and Hda3. These findings suggest a model through which hyphae-specific function is achieved by diminishing the concentration of key proteins of the Hda1 complex. We did not observe any changes in the RNA levels of *HDA1* and *HDA3* and therefore we hypothesise that translation efficiency and/or stability of these two proteins is differentially regulated in different environments.

Chromatin modifiers are often embedded in multiprotein complexes associated with several non-catalytic subunits that regulate their targeting to substrates or their catalytic activity (24). Our results highlight how Hda2 and Hda3, the non-catalytic subunits of the Hda1 complex, play important roles in regulating morphological switches in response to environmental changes.

Hda2 and Hda3 as potential targets for anti-fungal therapy

The yeast to hyphae switch is central to *C. albicans* virulence and pathogenesis. Our results signify that while Hda2 and Hda3 promote hyphae formation under specific growth conditions (RPMI and Spider media at 37 °C), they are dispensable for hyphae formation and virulence in the *C. elegans* infection system. We hypothesise

that this is due to the presence of redundant pathways that stimulate hyphae formation. Indeed, it has been shown that hyphae induction is a highly orchestrated process integrating several different environmental signals (13). The finding that, *in vivo*, lack of Hda2 and Hda3 does not impair hyphae formation is in agreement with the observation that strains mutant for the *YNG2* gene, the target of Hda1, also do not impair hyphae growth *in vivo* while they are defective for hyphae formation *in vitro* (27).

There is an urgent need to develop new anti-fungal drugs due to emergence of fungal strains resistant to currently available drugs. We propose that Hda2 and Hda3 could be targets for novel antifungal drugs to be used in combination therapy. Combination therapy offers several advantages compared to single-drug therapy. This is because it allows for widening of the spectrum and potency of drug activity and it can also lead to reduction in the dosage of individual agents preventing emergence of antifungal resistance (41). Several features make Hda2 and Hda3 attractive targets for antifungal drug development. First and most importantly, the proteins are present in fungi but absent in humans minimising potential toxicity. Secondly, drugs targeting Hda2 and Hda3 could have a broad spectrum of activity against a variety of human fungal pathogens as Hda2 and Hda3 orthologs are present in other human fungal pathogens, such as *C. glabrata* (CAGL0H01331g and CAGL0G09867g) and *A. fumigatus* (Hda2: Afu5g03390).

KDACs are emerging as promising candidates for drug development and several small molecules inhibiting KDAC activity are currently in clinical trials as potential anti-cancer therapeutics. We propose that inhibition of Hda2 and Hda3 will impair *C. albicans* Hda1 activity but not human KDACs reducing the risk of toxicity.

MATERIAL AND METHODS

Growth conditions

Strains are listed in Table 1. Yeast cells were cultured in rich medium (YPD) containing extra adenine (0.1 mg/ml) and extra uridine (0.08 mg/ml), complete SC medium (Formedium) or RPMI medium (Sigma-Aldrich). When indicated, media were supplemented with 30 µg/ml doxycycline. For analysis in stress conditions, YPD agar media was supplemented with 9 nM rapamycin, 2 M sodium chloride, 1 mM SNP with 1 mM SHAM, 7 mM copper sulphate, 300 mM lithium chloride, .01 % sodium dodecyl sulfate (SDS), 15mM caffeine, 1.5 M sorbitol, 18 mM cycloheximide, 1.5 mM cobalt, 25 mM hydroxyurea, 3 % ethanol, 20 µM Calcofluor White, 4.5 mM hydrogen peroxide, 0.75 mM EDTA and 2 µM Cerulenin (42). Cells were grown at 30 °C or 37 °C as indicated.

Plasmid construction

Oligos and plasmids used in this study are listed in Table 2 and 3. Plasmid ABp133 contains the *C. albicans HDA1* gene cloned in frame to a C-terminal HA tag. To generate this plasmid, the full length *HDA1* gene was amplified from plasmid ABp88 (synthesised by GeneArt) with oligos Abo408 and Abo409, containing recognition sites for *XmaI*. The digested PCR product was cloned into plasmid pHA-NAT (ABp17)(43) digested with *XmaI*. Cloning was confirmed by PCR and Sanger sequencing. *HDA3* was cloned in the pNIM plasmid (ABp111) (44) to generate plasmid ABp177. For this purpose, the full length *HDA3* gene was amplified from plasmid ABp152 (synthesised by GeneArt) with oligos ABo624 and ABo625, containing *XhoI* and *BglII* restriction sites. ABo625 also supplied a stop codon upstream the restriction site. This PCR fragment was cloned in pNIM digested with *SalI* and *BglII*. Cloning was confirmed by PCR and Sanger sequencing.

Construction of *C. albicans* mutants

Deletions of *HDA2* and *HDA3* were generated in the SN152 or BWP17 background using the *Clox* system for gene disruption (33) using long-oligos PCR, the LAL (loxP-ARG4-loxP) and NAT1-Clox (loxP-NAT1-MET3p-cre-loxP) plasmids as templates. During all selections for *Clox* transformants media was supplemented with 2.5 mM methionine and 2.5 mM cysteine to repress the *MET3* promoter and minimize Cre-loxP mediated recombination. Nourseothricin resistant (Nou^R) transformants were selected using 200 µg/ml nourseothricin (Melford). *HDA2* and *HDA3* gene deletions were confirmed by PCR and markers were resolved by allowing Cre expression in medium lacking methionine and cysteine as previously described (33). C-terminal GFP tagging of *HDA2* and *HDA3* genes at the endogenous loci was performed by long oligos PCR using plasmid pGFP-His1 (ABp11) as a template (45). C-terminal HA tagging of Hda1 was performed by long oligos PCR using plasmid ABp133 as a template and transformation into BWP17 (ABy215), *HDA2*-GFP (ABy532) and *HDA3*-GFP (ABy376). For rescue experiments, *HDA3* re-integrated at the *ADH* locus by digesting ABp177 with *KpnI* and *SacII* and transforming the product into the *hda3* Δ/Δ (Aby33) deletion strain. Correct integration was confirmed by colony PCR. Transformations of *C. albicans* strains were performed by electroporation using the protocol described in (46) or by lithium acetate transformation (47) of competent cells (48) with a *S. cerevisiae* method adapted to *C. albicans* (49).

Hyphal growth induction and quantification

Cultures were grown overnight (~16 hours) in 5 ml liquid YPD at 30 °C. Overnight cultures were diluted 1:100 in YPD media and grown ~5 hours at 30 °C. 50 – 100 cells were plated to RPMI or Spider agar and incubated for ~6 days at 37 °C. For doxycycline induction, the drug was added to the media at 30 µg/ml in 20 ml plates.

Phenotypes were documented by imaging with a Leica MZFLIII microscope at 10x to 16x magnification. A minimum of 150 colonies were counted for each strain. For liquid filamentation assays, overnight cultures were grown throughout the day and from this stationary culture, 1 mL was harvested and washed with distilled water before resuspending in 10 mL pre-warmed final media (YPD (control) or RPMI). These cultures were grown at 37 °C (control at 30 °C) for 15-17 hours before imaging on an Olympus IX81 inverted microscope at 60x magnification. Samples were evaluated on four separate days and a minimum of 400 cells were counted per sample.

White-opaque switching essay

Quantitative switching assays were performed as previously described (12) with modifications. Briefly, strains were streaked from frozen stocks on YPD plates and grown at 30 °C for 2 days. Single colonies were picked, resuspended in sterile water and spread onto synthetic complete agar containing 5 µg/ml Phloxine B (Sigma-Aldrich). Formation of opaque colonies or sectors was scored after 9 days. Experiments were done in biological duplicate or triplicate on at least three separate days. A minimum of 400 total colonies were counted for each strain. The ggplot package in R studio was used to construct violin plots. Unpaired t-tests were performed to test for significant differences between wild-type and mutant strains.

Structural modelling

The model of Hda3 DBD and CCS domain was produced using Phyre2 in intensive mode (50) and visualised using PyMol (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.)

Whole cell extracts

Preparation of whole cell extracts was performed as described (51). Briefly, overnight YPD cultures were diluted in YPD or RPMI and grown to $OD_{600} = \sim 0.8$ at 30 °C. Cells were harvested, resuspended in 200 μ l lysis buffer (0.1 M NaOH, 0.05 M EDTA, 2 % SDS, 2% β -mercaptoethanol) and heated for 10 minutes at 95 °C before adding 5 μ l of 4 M Acetic acid and incubating for further 10 minutes at 90 °C. Extracts were mixed with 50 μ l loading buffer (0.25 M Tris-HCl pH 6.8, 50 % Glycerol, 0.05 % Bromophenol Blue), incubated at 96 °C for 5 minutes and centrifuged at 13000 rpm for 5 minutes. Supernatants were collected and analysed by SDS-PAGE and Western blot analyses.

Immunoprecipitation

Immunoprecipitation was performed as described (52) with modifications. 1 L YPD cultures ($OD_{600} = 1$) were harvested at 4000 rpm. Cell were washed 3 times in cold water and resuspended in 1/5th volume (water/cells). Cell pellets were ground in liquid nitrogen using a mortar and pestle for 30 minutes and resuspended in 10 ml of cold lysis buffer (50 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.1 % NP-40, 5 mM DTT, 1x Roche EDTA-free protease inhibitor cocktail and 0.2 mM PMSF added fresh before use). The cells were solubilized for 30 minutes with rotation at 4 °C. Following centrifugation, supernatant samples were incubated with 4 μ l of magnetic beads pre-coupled with anti-HA antibody (Sigma-Aldrich) for 2 hours with rotation at 4 °C. Beads were washed four times in lysis buffer and analysed by SDS-PAGE and Western blot.

Antibodies information

The following antibodies were used for Western analyses. Anti-HA antibody (#11666606001, Sigma-Aldrich) diluted at 1:1000, anti-GFP antibody (Roche

#1184460001) diluted at 1:5000, anti-actin (Cooper Lab, Washington University, St. Louis, Mo., USA) diluted at 1:5000.

RNA extraction

Overnight YPD cultures were diluted in YPD and grown to $OD_{600} = \sim 0.8$. Cells were pelleted, washed once with sterile water and resuspended in pre-warmed YPD (30 °C) or RPMI (37 °C) for 90 minutes. RNA extraction was performed using a yeast RNA extraction kit (E.Z.N.A. Isolation Kit RNA Yeast, Omega Bio-Tek) following the manufacturer's instructions with the following modifications: (1) 30 °C incubation in SE Buffer/2-mercaptoethanol/lyticase solution time was increased to 90 minutes; (2) lysis was performed with bead mill at top speed for 30 minutes at 4°C. RNA was treated with DNase I and RNA quality was checked by electrophoresis under denaturing conditions in 1% agarose, 1× HEPES, 6% Formaldehyde (Sigma-Aldrich). RNA concentration was measured using a NanoDrop ND-1000 Spectrophotometer. cDNA synthesis was performed using qPCRBIO cDNA Synthesis Kit (PCR Biosystems) following manufacturer's instructions.

High-throughput RNA sequencing

Strand-specific cDNA Illumina Barcoded Libraries were generated from 1 µg of total RNA extracted from WT, *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ and sequenced with an Illumina iSeq2000 platform. Illumina library preparation and deep-sequencing was performed by the Genomics Core Facility at EMBL (Heidelberg, Germany). RNA sequencing was performed in duplicates. Raw reads were analysed following the RNA deep sequencing analysis pipeline using the Galaxy platform (<https://usegalaxy.org/>). Downstream analysis of differential expressed genes was performed with R Studio (<https://www.rstudio.com/>). Scatter Plot matrices, using Pearson correlation coefficients, were generated with the ggplot

package. Heatmaps were generated with the pheatmap package and Pearson correlation for clustering. Heatmaps show the log2 fold changes of differentially expressed genes in *hda1* Δ/Δ , *hda2* Δ/Δ or *hda3* Δ/Δ compared to wild-type expression. Venn diagrams were generated using the FunRich programme(53). RNA sequencing data are deposited into ArrayExpress (accession number: E-MTAB-6920).

qRT-PCR

qRT-PCR was performed in the presence of SYBR Green (Bio-Rad) on a Bio-Rad CFXConnect Real-Time System. Data was analysed with Bio-Rad CFX Manager 3.1 software and Microsoft Excel. Enrichment was calculated over actin. Histograms represent data from three biological replicates. Error bars: standard deviation of three biological replicates generated from 3 independent cultures of the same strain.

Functional analysis and modelling of transcriptional profiles

Gene set enrichment analysis (GSEA) (34, 54) was performed using the GSEA PreRanked tool to determine whether a ranked gene list exhibited statistically significant bias in their distribution within defined gene sets (55) and (*Sellam et al*, personal communication). The weighted enrichment statistics were calculated on 10512 gene sets each containing 5-1000 genes, and the false discovery rate (FDR) was calculated from 1000 permutations. Selected results graphs are shown. Since enrichment profiles can exhibit correlations with hundreds of overlapping gene sets, Cytoscape 3.6 (<http://www.cytoscape.org>) (56) and the Enrichment Map Pipeline Collection plug-ins (<http://apps.cytoscape.org/apps/enrichmentmappipelinecollection>) were used to further organise and visualise the GSEA. Enrichment maps were calculated using default parameters.

C. albicans-*C. elegans* pathogenesis assay

The *C. elegans glp-4/sek-1* strain was used as described previously (39, 57). Briefly, *C. elegans* were propagated on nematode growth medium (NGM) on lawns of *E. coli* OP50. The *C. albicans*-*C. elegans* pathogenesis assay was performed as previously described (40). Briefly, 100 µl of *C. albicans* cells from an overnight culture were spread into a square lawn on a 10 cm plate containing brain-heart infusion (BHI) agar and kanamycin (45 µg/ml). These were incubated for approximately 20 hours at 30 °C. Synchronized adult *C. elegans glp-4/sek-1* nematodes grown at 25°C were carefully washed from NGM plates using sterile M9 buffer. Approximately 100 to 200 washed animals were then added to the centre of the *C. albicans* lawns and the plates were incubated at 25°C for 4 hours. Worms were then carefully washed into a 15 ml tube using 10 ml of sterile M9, taking care to minimize the transfer of yeast. Worms were washed four or five times with sterile M9. 30-40 worms were then transferred into three wells of a six-well tissue culture plate (Corning, Inc.) containing 2 ml of liquid medium (80% M9, 20% BHI) and kanamycin (45 µg/ml). Worms were scored daily into one of three categories: alive, dead with hyphae piercing the cuticle, and dead without hyphae piercing the cuticle. Worms were considered to be dead if they did not move in response to mechanical stimulation with a pick. Dead worms were removed from the assay. *C. elegans* survival was examined by using the Kaplan-Meier method and differences were determined by using the log-rank test using OASIS 2 tool (58). Differences in the number of worms with *C. albicans* hyphal formation were determined by using a one-way ANOVA with Dunnett's test for multiple comparisons. The *C. elegans* pathogenesis assay presented here is an average of three independent biologic replicates. A p-value of <0.05 was considered statistically significant.

FUNDING INFORMATION

537 A.B and R.J.P: Medical Research Council [MR/M019713/1]; S.G: [BB/L008041/1].
538 Funding for open access charge: University of Kent.

539 **ACKNOWLEDGMENTS**

540 We thank GeneCore at EMBL for performing Illumina library preparation and
541 sequencing. We thank Dr Sellam (Biotechnology Research Institute, National
542 Research Council of Canada) and Dr Traven (Monash University) for help with the
543 GSEA analysis. We are grateful to Dr Anderson (The Ohio State University) for the
544 plasmid allowing deletion of mating type cassette and Prod Alistair Brown (University
545 of Aberdeen) for the Clox system. We thank members of the Kent Fungal Group for
546 useful discussions and critical reading of the manuscript.

547

548 **REFERENCES**

- 549 1. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. 2012.
550 Hidden Killers: Human Fungal Infections. *Sci Transl Med* 4:165rv13-165rv13.
- 551 2. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North
552 America. *Crit Rev Microbiol* 36:1–53.
- 553 3. Slutsky B, Staebell M, Anderson J, Risen L, Pfaller M, Soll DR. 1987.
554 “White-opaque transition”: a second high-frequency switching
555 system in *Candida albicans*. *J Bacteriol* 169:189–97.
- 556 4. Bennett RJ, Johnson a D. 2005. Mating in *Candida albicans* and the search
557 for a sexual cycle. *Annu Rev Microbiol* 59:233–55.
- 558 5. Kvaal C, Lachke SA, Srikantha T, Daniels K, McCoy J, Soll DR. 1999.
559 Misexpression of the opaque-phase-specific gene PEP1 (SAP1) in the white

- 560 phase of *Candida albicans* confers increased virulence in a mouse model of
561 cutaneous infection. *Infect Immun* 67:6652–62.
- 562 6. Kvaal CA, Srikantha T, Soll DR. 1997. Misexpression of the white-phase-
563 specific gene WH11 in the opaque phase of *Candida albicans* affects switching
564 and virulence. *Infect Immun* 65:4468–75.
- 565 7. Lachke SA, Lockhart SR, Daniels KJ, Soll DR. 2003. Skin facilitates *Candida*
566 *albicans* mating. *Infect Immun* 71:4970–6.
- 567 8. Huang G, Wang H, Chou S, Nie X, Chen J, Liu H. 2006. Bistable expression of
568 WOR1, a master regulator of white-opaque switching in *Candida albicans*.
569 *Proc Natl Acad Sci* 103:12813–12818.
- 570 9. Srikantha T, Borneman AR, Daniels KJ, Pujol C, Wu W, Seringhaus MR,
571 Gerstein M, Yi S, Snyder M, Soll DR. 2006. TOS9 Regulates White-Opaque
572 Switching in *Candida albicans*. *Eukaryot Cell* 5:1674–1687.
- 573 10. Zordan RE, Miller MG, Galgoczy DJ, Tuch BB, Johnson AD. 2007. Interlocking
574 Transcriptional Feedback Loops Control White-Opaque Switching in *Candida*
575 *albicans*. *PLoS Biol* 5:e256.
- 576 11. Zordan RE, Galgoczy DJ, Johnson AD. 2006. Epigenetic properties of white-
577 opaque switching in *Candida albicans* are based on a self-sustaining
578 transcriptional feedback loop. *Proc Natl Acad Sci U S A* 103:12807–12.
- 579 12. Miller MG, Johnson AD. 2002. White-opaque switching in *Candida albicans* is
580 controlled by mating-type locus homeodomain proteins and allows efficient
581 mating. *Cell* 110:293–302.
- 582 13. Noble SM, Gianetti BA, Witchley JN. 2017. *Candida albicans* cell-type

- switching and functional plasticity in the mammalian host. Nat Rev Microbiol
15:96–108.
14. Staab JF, Bradway SD, Fidel PL, Sundstrom P. 1999. Adhesive and
mammalian transglutaminase substrate properties of *Candida albicans* Hwp1.
Science 283:1535–8.
15. Almeida RS, Brunke S, Albrecht A, Thewes S, Laue M, Edwards JE, Filler SG,
Hube B. 2008. The Hyphal-Associated Adhesin and Invasin Als3 of *Candida*
albicans Mediates Iron Acquisition from Host Ferritin. PLoS Pathog
4:e1000217.
16. Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, Welch WH, Ibrahim
AS, Edwards JE, Filler SG. 2007. Als3 Is a *Candida albicans* Invasin That
Binds to Cadherins and Induces Endocytosis by Host Cells. PLoS Biol 5:e64.
17. Weissman Z, Kornitzer D. 2004. A family of *Candida* cell surface haem-binding
proteins involved in haemin and haemoglobin-iron utilization. Mol Microbiol
53:1209–1220.
18. Braun BR, Kadosh D, Johnson AD. 2001. NRG1, a repressor of filamentous
growth in *C. albicans*, is down-regulated during filament induction. EMBO J
20:4753–4761.
19. Lu Y, Su C, Wang A, Liu H. 2011. Hyphal Development in *Candida albicans*
Requires Two Temporally Linked Changes in Promoter Chromatin for Initiation
and Maintenance. PLoS Biol 9:e1001105.
20. Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and
priorities. Trends Microbiol 18:195–204.

- 606 21. Kurdistan SK, Grunstein M. 2003. Histone acetylation and deacetylation in
607 yeast. *Nat Rev Mol Cell Biol* 4:276–284.
- 608 22. Glozak MA, Sengupta N, Zhang X, Seto E. 2005. Acetylation and
609 deacetylation of non-histone proteins. *Gene* 363:15–23.
- 610 23. Haberland M, Montgomery RL, Olson EN. 2009. The many roles of histone
611 deacetylases in development and physiology: Implications for disease and
612 therapy. *Nat Rev Genet* 10:32–42.
- 613 24. Falkenberg KJ, Johnstone RW. 2014. Histone deacetylases and their inhibitors
614 in cancer, neurological diseases and immune disorders. *Nat Rev Drug Discov*
615 13:673–691.
- 616 25. Srikantha T, Tsai L, Daniels K, Klar AJS, Soll DR. 2001. The Histone
617 Deacetylase Genes HDA1 and RPD3 Play Distinct Roles in Regulation of
618 High-Frequency Phenotypic Switching in *Candida albicans*. *Society* 183:4614–
619 4625.
- 620 26. Hnisz D, Schwarzmüller T, Kuchler K. 2009. Transcriptional loops meet
621 chromatin: a dual-layer network controls white-opaque switching in *Candida*
622 *albicans*. *Mol Microbiol* 74:1–15.
- 623 27. Lu Y, Su C, Solis N V., Filler SG, Liu H. 2013. Synergistic regulation of hyphal
624 elongation by hypoxia, CO₂, and nutrient conditions controls the virulence of
625 *Candida albicans*. *Cell Host Microbe* 14:499–509.
- 626 28. Kadosh D, Lopez-Ribot JL. 2013. *Candida albicans*: Adapting to Succeed. *Cell*
627 *Host Microbe* 14:483–485.
- 628 29. Tzogani K, van Hennik P, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson

- 629 T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. 2018. EMA Review
630 of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed
631 and/or Refractory Multiple Myeloma. *Oncologist* 23:631–636.
- 632 30. Simó-Riudalbas L, Esteller M. 2015. Targeting the histone orthography of
633 cancer: drugs for writers, erasers and readers. *Br J Pharmacol* 172:2716–
634 2732.
- 635 31. Wu J, Carmen a a, Kobayashi R, Suka N, Grunstein M. 2001. HDA2 and
636 HDA3 are related proteins that interact with and are essential for the activity of
637 the yeast histone deacetylase HDA1. *Proc Natl Acad Sci U S A* 98:4391–6.
- 638 32. Lee JH, Maskos K, Huber R. 2009. Structural and Functional Studies of the
639 Yeast Class II Hda1 Histone Deacetylase Complex. *J Mol Biol* 391:744–757.
- 640 33. Shahana S, Childers DS, Ballou ER, Bohovych I, Odds FC, Gow N a R, Brown
641 AJP. 2014. New Clox Systems for rapid and efficient gene disruption in
642 *Candida albicans*. *PLoS One* 9:e100390.
- 643 34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
644 Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set
645 enrichment analysis: a knowledge-based approach for interpreting genome-
646 wide expression profiles. *Proc Natl Acad Sci U S A* 102:15545–50.
- 647 35. Sellam A, van het Hoog M, Tebbji F, Beaurepaire C, Whiteway M, Nantel A.
648 2014. Modeling the transcriptional regulatory network that controls the early
649 hypoxic response in *Candida albicans*. *Eukaryot Cell* 13:675–90.
- 650 36. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. 2010. Enrichment Map: A
651 Network-Based Method for Gene-Set Enrichment Visualization and

- 652 Interpretation. PLoS One 5:e13984.
- 653 37. Enjalbert B, Nantel A, Whiteway M. 2003. Stress-induced gene expression in
654 *Candida albicans*: absence of a general stress response. Mol Biol Cell
655 14:1460–7.
- 656 38. Tuch BB, Mitrovich QM, Homann OR, Hernday AD, Monighetti CK, De La
657 Vega FM, Johnson AD. 2010. The transcriptomes of two heritable cell types
658 illuminate the circuit governing their differentiation. PLoS Genet 6:e1001070.
- 659 39. Breger J, Fuchs BB, Aperis G, Moy TI, Ausubel FM, Mylonakis E. 2007.
660 Antifungal Chemical Compounds Identified Using a *C. elegans* Pathogenicity
661 Assay. PLoS Pathog 3:e18.
- 662 40. Pukkila-Worley R, Peleg AY, Tampakakis E, Mylonakis E. 2009. *Candida*
663 *albicans* hyphal formation and virulence assessed using a *Caenorhabditis*
664 *elegans* infection model. Eukaryot Cell 8:1750–8.
- 665 41. Lewis RE, Kontoyiannis DP. 2001. Rationale for combination antifungal
666 therapy. Pharmacotherapy 21:149S–164S.
- 667 42. Homann OR, Dea J, Noble SM, Johnson AD. 2009. A phenotypic profile of the
668 *Candida albicans* regulatory network. PLoS Genet 5.
- 669 43. Gerami-nejad M, Forche A, McClellan M, Berman J. 2012. Analysis of protein
670 function in clinical *C. albicans* isolates 5314.
- 671 44. Park Y, Park Y, Morschhauser J, Morschhauser J. 2005. Tetracycline-
672 Inducible Gene Expression and Gene Deletion in *Candida albicans*.
673 Microbiology 4:1328–1342.
- 674 45. Gerami-Nejad M, Berman J, Gale CA. 2001. Cassettes for PCR-mediated

- 675 construction of green, yellow, and cyan fluorescent protein fusions in *Candida*
- 676 *albicans*. *Yeast* 18:859–864.
- 677 46. De Backer MD, Maes D, Vandoninck S, Logghe M, Contreras R, Luyten
- 678 WHML. 1999. Transformation of *Candida albicans* by Electroporation. *Yeast*
- 679 15:1609–1618.
- 680 47. Schiestl RH, Gietz RD. 1989. High efficiency transformation of intact yeast
- 681 cells using single stranded nucleic acids as a carrier. *Curr Genet* 16:339–346.
- 682 48. Knop M, Siegers K, Pereira G, Zachariae W, Winsor B, Nasmyth K, Schiebel
- 683 E. 1999. Epitope tagging of yeast genes using a PCR-based strategy: more
- 684 tags and improved practical routines. *Yeast* 15:963–972.
- 685 49. Walther A, Wendland J. 2003. An improved transformation protocol for the
- 686 human fungal pathogen *Candida albicans*. *Curr Genet* 42:339–343.
- 687 50. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. 2015. The Phyre2
- 688 web portal for protein modeling, prediction and analysis. *Nat Protoc* 10:845–
- 689 58.
- 690 51. von der Haar T. 2007. Optimized protein extraction for quantitative proteomics
- 691 of yeasts. *PLoS One* 2:e1078.
- 692 52. Buscaino A, White SA, Houston DR, Lejeune E, Simmer F, de Lima Alves F,
- 693 Diyora PT, Urano T, Bayne EH, Rappsilber J, Allshire RC. 2012. Raf1 Is a
- 694 DCAF for the Rik1 DDB1-Like Protein and Has Separable Roles in siRNA
- 695 Generation and Chromatin Modification. *PLoS Genet* 8:e1002499.
- 696 53. Pathan M, Keerthikumar S, Chisanga D, Alessandro R, Ang C-S, Askenase P,
- 697 Batagov AO, Benito-Martin A, Camussi G, Clayton A, Collino F, Di Vizio D,

- 698 Falcon-Perez JM, Fonseca P, Fonseca P, Fontana S, Gho YS, Hendrix A,
699 Hoen EN-t, Iraci N, Kastaniegaard K, Kislinger T, Kowal J, Kurochkin I V.,
700 Leonardi T, Liang Y, Llorente A, Lunavat TR, Maji S, Monteleone F, Øverbye
701 A, Panaretakis T, Patel T, Peinado H, Pluchino S, Principe S, Ronquist G,
702 Royo F, Sahoo S, Spinelli C, Stensballe A, Théry C, van Herwijnen MJC,
703 Wauben M, Welton JL, Zhao K, Mathivanan S. 2017. A novel community
704 driven software for functional enrichment analysis of extracellular vesicles
705 data. J Extracell Vesicles 6:1321455.
- 706 54. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J,
707 Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ,
708 Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES,
709 Hirschhorn JN, Altshuler D, Groop LC. 2003. PGC-1alpha-responsive genes
710 involved in oxidative phosphorylation are coordinately downregulated in human
711 diabetes. Nat Genet 34:267–73.
- 712 55. Sellam A, Hogues H, Askew C, Tebbji F, van Het Hoog M, Lavoie H,
713 Kumamoto C a, Whiteway M, Nantel A. 2010. Experimental annotation of the
714 human pathogen *Candida albicans* coding and noncoding transcribed regions
715 using high-resolution tiling arrays. Genome Biol 11:R71.
- 716 56. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
717 Schwikowski B, Ideker T. 2003. Cytoscape: A Software Environment for
718 Integrated Models of Biomolecular Interaction Networks. Genome Res
719 13:2498–2504.
- 720 57. Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, Ausubel FM. 2006.
721 Identification of novel antimicrobials using a live-animal infection model. Proc

- Natl Acad Sci U S A 103:10414–10419.
58. Han SK, Lee D, Lee H, Kim D, Son HG, Yang J-S, Lee S-J V., Kim S. 2016. OASIS 2: online application for survival analysis 2 with features for the analysis of maximal lifespan and healthspan in aging research. *Oncotarget* 7:56147–56152.
59. Synnott JM, Guida A, Mulhern-Haughey S, Higgins DG, Butler G. 2010. Regulation of the Hypoxic Response in *Candida albicans*. *Eukaryot Cell* 9:1734–1746.
60. Marcil A, Gadoury C, Ash J, Zhang J, Nantel A, Whiteway M. 2008. Analysis of PRA1 and its relationship to *Candida albicans*-macrophage interactions. *Infect Immun* 76:4345–4358.
61. Noble SM, Johnson AD. 2005. Strains and Strategies for Large-Scale Gene Deletion Studies of the Diploid Human Fungal Pathogen *Candida albicans* *Eukaryot Cell* 4: 298-309
62. Wilson RB, Davis D, Mitchell AP. 1999. Rapid Hypothesis Testing with *Candida albicans* through Gene Disruption with Short Homology Regions *Journal of bacteriology* 181: 1868-74

FIGURE LEGENDS

Figure 1. The Hda1 complex is conserved in *C. albicans*

(A) Domain organisation of *C. albicans* Hda2 and Hda3 proteins (B) Left: Structural alignment of *C. albicans* DBD3 domain (red) with *S. cerevisiae* DBD3 domain

(yellow); *Right*: Structural modelling of *C. albicans* CCD3 **(C)** Co-
Immunoprecipitation of Hda1 with Hda2 and Hda3. Hda1-HA Immunoprecipitation
(Ip) analysed with anti-HA or with anti-GFP to detect Hda2 and Hda3. **(D)** Schematic
of *Clox* gene disruption strategy used to construct *hda2* Δ/Δ and *hda3* Δ/Δ mutants.
(E) Serial dilution assay of WT, *hda2* Δ/Δ and *hda3* Δ/Δ mutants on solid YPD media
at 30 °C. **(F)** Growth curves of WT, *hda2* Δ/Δ and *hda3* Δ/Δ isolates in YPD liquid
media at 30 °C.

Figure 2. Global gene expression changes in the absence of Hda2 and Hda3

(A) Pearson correlation matrix of gene expression changes observed in *hda1* Δ/Δ ,
hda2 Δ/Δ and *hda3* Δ/Δ grown in YPD at 30 °C. r = Pearson correlation coefficient. p
= p-value. **(B)** The network of functional groups of genes regulated by Hda2 and
Hda3 constructed by GSEA and Enrichment Map. Blue circles represent down
regulated while orange circles depict upregulated gene sets which are linked in the
network by grey lines. The diameter of the circles varies based upon the number of
transcripts within each set. **(C)** Example enrichment plots for selected genes sets
differentially expressed in *hda2* Δ/Δ (left) and *hda3* Δ/Δ (right). Ketoconazole_up: set
of genes upregulated in *C. albicans* cells grown in the presence of ketoconazole
(59); Phagocytosis_up: gene set upregulated following engulfment by primary Bone
Marrow Derived Macrophages (60). The x-axis shows genes ranked according to
their expression in the mutants from up-regulated (left) to down-regulated (right)
genes. Black vertical lines mark individual genes. The cumulative value of the
enrichment score (y-axis) is represented by the green line. A positive normalised
enrichment score (NES) indicates enrichment in the up-regulated group of genes in
hda2 Δ/Δ and *hda3* Δ/Δ .

Figure 3. Phenotyping of *hda2* Δ/Δ and *hda3* Δ/Δ strains

Serial dilution assay showing growth of *hda2* Δ/Δ and *hda3* Δ/Δ mutants on solid YPD media with additives as indicated and incubation at 30 °C for 2 - 4 days. **(A)** Additives affecting *hda2* Δ/Δ and *hda3* Δ/Δ growth relative to wildtype strain. Mutants are resistant to rapamycin and sensitive to SNP and SHAM, sodium chloride and copper sulphate. **(B)** Conditions eliciting normal growth of mutant strains relative to matching wildtype.

Figure 4. Hda2 and Hda3 inhibit white-opaque switching

(A) Enrichment plots for genes differentially expressed in *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ in comparison to genes upregulated in opaque cells (38). The x-axis shows genes ranked according to their expression in the mutants from up-regulated (left) to down-regulated (right) genes. Black vertical lines mark individual genes. The cumulative value of the enrichment score (y-axis) is represented by the green line. A positive normalised enrichment score (NES) indicates enrichment in the up-regulated group of genes in *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ . **(B)** Heat map depicting the log2 fold change in *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ isolates compared to WT for the Opaque_up gene set. **(C)** Log2 fold change values and significance for *WOR1* gene expression in *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ compared to WT. **(D) Left:** Percentage of sector colonies in WT, *hda2* Δ/Δ and *hda3* Δ/Δ isolates. ** = p value $\leq$.01. **Right:** Representative image of cells grown on Phloxine B agar. O = opaque; W = white.

Figure 5. Gene expression profiling in hyphae-inducing conditions in WT, *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ isolates

(A) The network representing changes in gene expression in WT cells grown in yeast-inducing conditions (YPD) versus hyphae-inducing conditions (RPMI) constructed by GSEA and Enrichment Map. Blue circles represent down regulated gene sets, while orange depicts upregulated gene sets which are linked in the network by grey lines that indicate function. The diameter of the circles varies based upon the number of transcripts within each set. **(B)** Pearson correlation matrix of gene expression changes observed in *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ grown in in hyphae growth media (RPMI) at 37 °C. r = Pearson correlation coefficient. p = p -value. **(C)** *Left:* Heat map depicting the log2 fold change in WT cells grown in hyphae-inducing conditions (RPMI at 37 °C) versus WT cells grown in yeast-inducing conditions (YPD at 30 °C). Gene known to be involved in hyphae formation or biofilm formation are indicated. *Right:* Log2 fold changes of hyphae-induced and repressed-genes in *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ isolates. Cells were grown in RPMI at 37 °C. **(D)** Quantitative reverse transcriptase PCR (qRT-PCR) analyses to measure *HWP1* and *ALS3* transcript levels in WT, *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ isolates grown in yeast (YPD at 30 °C) or hyphae (RPMI at 37 °C) inducing conditions. Transcripts levels are visualized relative to *ACT1* transcript levels. Error bars in each panel: standard deviation of three biological replicates.

Figure 6. Hda2 and Hda3 contribute to filamentation growth but not virulence

(A) *Left:* Representative images of colony morphology of WT, *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ grown on hyphal inducing Spider and RPMI agar at 37 °C. *Right:* Quantification of colony morphologies. **(B)** Quantification of cellular morphologies of WT, *hda1* Δ/Δ , *hda2* Δ/Δ and *hda3* Δ/Δ grown in liquid RPMI media at 37 °C. **(C)** Rescue experiment of colony morphology upon genomic integration of the *HDA3* gene in the *hda3* Δ/Δ mutant background (*hda3* Δ/Δ + *HDA3*). WT, heterozygous

(*HDA3*/ *hda3* Δ) and homozygous *hda3* Δ/Δ isolates were included as a control. Cell were grown on hyphal inducing RPMI agar at 37 °C. **(D)** *Left*: Representative images of dead *C. elegans* with and without hyphae-mediated killing. *Middle*: Survival curve of worms incubated with WT, *hda2* Δ/Δ and *hda3* Δ/Δ strains over a 72 hour period. *Right*: The percentage of total worms dead (black bars) and worms killed by hyphae piercing the cuticle (grey bars) after the 72 hour incubation period. Error bars represent the standard deviation of three independent biological replicates.

Figure 7. Stability of the Hda1 protein is regulated by environmental changes

(A) Venn diagram of genes differentially expressed in *hda1* Δ/Δ relative to WT in yeast and hyphal growth conditions. **(B)** Enrichment plots for genes differentially expressed in *hda1* Δ/Δ relative to genes downregulated (Hyphae_Lee_DN) or upregulated (Hyphae_Lee_up) in hyphae-growth condition in Lee's media . The x-axis shows genes ranking according to their expression in *hda1* Δ/Δ from up-regulated (left) to down-regulated (right) genes. Black vertical lines mark individual genes. The cumulative value of the enrichment score (y-axis) is represented by the green line. A positive normalised enrichment score (NES) indicates enrichment in the up-regulated group of genes while a negative NES indicates prevalence of the genes in the down-regulated group. **(C)** HA and GFP Western blots of whole protein extract from strains: Hda1-HA, Hda2-GFP and Hda3-GFP. Actin is shown as a loading control. Cells were grown in yeast (YPD 30 °C) or hyphae-inducing (RPMI 37 °C) conditions. **(D)** Model showing how decreased Hda1 and Hda3 protein levels leading to the functional rewiring of the Hda1 complex in *C. albicans* in different environments. Under yeast growth condition, the Hda1 complex functions as a global regulator of gene expression due to the high level of Hda1 and Hda3. Under hyphae

growth conditions, decreased levels of Hda1 and Hda3 leads to specialisation of the Hda1 complex controlling only filamentous growth.

Table 1. *C.albicans* strains used in this study.

Strain Number	Description	Genotype	Figure	Source
ABy_54	SN152	<i>MTL a/alpha ura3Δ-iro1Δ::imm434/URA3-IRO1 his1Δ/his1Δ arg4Δ/arg4Δ leu2Δ/leu2Δ</i>	1E-F, 2A-C, 3A-B, 4A-C, 5A-D, 6A-B, 6D, 7A-B	(61)
ABy_66	BWP17	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG</i>	1F, 6B-C	(62)
ABy_179	<i>hda1 Δ/Δ</i>	<i>MTL a/a arg4Δ/arg4Δ his1Δ/his1Δ leu2Δ/leu2Δ URA3/ura3Δ::λimm434IRO1 /iro1Δ::λimm434 hda1Δ::C.d.HIS1/hda1Δ::C.m.LEU2</i>	2A-C, 3A-B, 4A-C, 5A-D, 6A-B, 6D, 7A-B	(26)
ABy_191	HDA3/Δ	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG HDA3/hda3Δ::LAL</i>	6C	This study
ABy_331	BWP17 <i>hda3Δ/Δ</i>	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG hda3Δ/hda3Δ</i>	1F, 6B-C	This study
ABy_347	<i>hda2Δ/Δ</i>	<i>MTL a/alpha ura3Δ-iro1Δ::imm434/URA3-IRO1 his1Δ/his1Δ arg4Δ/arg4Δ leu2Δ/leu2Δ hda2Δ/hda2Δ</i>	1E-F, 2A-C, 3A-B, 4A-D, 5A-C, 6B, 6D, 6A	This study
ABy_376	<i>HDA3:HDA3-GFP</i>	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG HDA3::HIS/HDA3-GFP</i>	1C, 7C	This study
ABy_393	BWP17 <i>MTLαΔ</i>	<i>MTLa/MTLalphaΔ ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG</i>	4D	This study

ABy_460	SN152 <i>hda3Δ/Δ</i>	<i>MTL a/alpha ura3Δ-iro1Δ::imm434/URA3-IRO1 his1Δ/his1Δ arg4Δ/arg4Δ leu2Δ/leu2Δ hda3Δ/hda3Δ</i>	1E, 2A-C, 3A-B, 4A-C, 5A-D, 6A-B, 6D	This study
ABy_472	<i>ADH1/ pNIM-HDA3:adh1Δ</i>	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG hda3Δ/hda3Δ pNIM-HDA3::adh1Δ/ADH1</i>	6C	This study
ABy_532	<i>HDA2:HDA2-GFP</i>	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG HDA2::HIS/HDA2-GFP</i>	1C, 7C	This study
ABy_536	<i>HDA2:HDA2-GFP HDA1:HDA1-HA</i>	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG HDA2::HIS/HDA2-GFP HDA1::NAT/HDA1-HA</i>	1C	This study
ABy_539	<i>HDA3:HDA3-GFP HDA1:HDA1-HA</i>	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG HDA3::HIS/HDA3-GFP HDA1::NAT/HDA1-HA</i>	1C	This study
ABy_547	<i>hda2Δ/Δ MTLαΔ</i>	<i>MTL a/ MTLalphaΔ ura3Δ-iro1Δ::imm434/URA3-IRO1 his1Δ/his1Δ arg4Δ/arg4Δ leu2Δ/leu2Δ hda2Δ/hda2Δ</i>	4D	This study
ABy_551	<i>hda3Δ/Δ MTLαΔ</i>	<i>MTL a/ MTLalphaΔ ura3Δ-iro1Δ::imm434/URA3-IRO1 his1Δ/his1Δ arg4Δ/arg4Δ leu2Δ/leu2Δ hda3Δ/hda3Δ</i>	4D	This study
ABy_563	<i>HDA1:HDA1-HA</i>	<i>MTL a/alpha ura3Δ::Δimm434/ura3Δ::Δimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG HDA1::NAT/HDA1-HA</i>	1C, 7C	This study

846

847 **Table 2.** Oligos used in this study.

Number	Primer	Sequence	Figure	Description
ABo_408	HDA1_Xma_fw1	TAAGCACCCGGGatgtcgactggtaagaagaa	1C, 7C-D	Isolate synthetic Hda1 from p88
ABo_409	HDA1_Xma_rev1	TAAGCACCCGGGatctt	1C, 7C-D	Isolate synthetic Hda1

		cggaagaggagtagtc		from p88
ABo_351	Pr_sir2_adh1	CGCACTCACGTAAAC ACTT	1C, 6C, 7C-D	Check Hda1 in p17; confirm reintegration of Hda3_pNIM cassette at ADH1 locus
ABo_412	HDA1end_chkseq	GGAAATAGTTCGAAC GGTGG	1C, 7C-D	Check Hda1 in p17; sequencing p133
ABo_452	F1gaHDA1_Haintg	TCCGAAATTCATTATT AAGGAATTATATAGA AGCTACCATTTCAC ATCTATTATCATTTTC CTTTTAAAGAatgtcgact ggtcaagaagaaca	1C, 7C-D	Isolate Hda1-HA integration cassette from p133; long oligo
ABo_453	R1gaHDA1_Haintg	CAGATCTATATCTATT CTCTTTCTTTCTTTT TTTTGGTTTTTGTG TTGTTGTTGTTGTTTC TACTCGAAGtaaacga cggccagtgaattc	1C, 7C-D	Isolate Hda1-HA integration cassette from p133; long oligo
ABo_179	PR1_NAT	CTGTATCTATAAGCA GTATCATCC	1C, 7C-D	Check presence of Hda1-HA integration cassette at native locus
ABo_417	dwnstrmHDA1rev_ check	CTCGATGCCTGATTT GGATG	1C, 7C-D	Check presence of Hda1-HA integration cassette at native locus
ABo_458	F1HDA2_GFP	TGTTAGAAAACCTCTG GCTCGGGTGCCAATA ATAGACAAAATAATC GTATTAGTCGAGGTG CAACACCTCTTGGTG GTGGTtctaaaggtgaaga attatt	1C, 7C-D	Isolate GFP tagging cassette from p11 with flanking integration sequences for Hda2; long oligo
ABo_459	R2HDA2_GFP	GCATGTATTTACAAA TTTTTGATAAGAAA AAGTAGCATATGGAA ACACAAAACCAAGAA AGAAATCATGgaattcc ggaatatttatgagaaac	1C, 7C-D	Isolate GFP tagging cassette from p11 with flanking integration sequences for Hda2; long oligo
ABo_460	F1HDA3_GFP	CAATGCTTTTACATTT TTAAATGATACTAAAT ATTTGAAAAAGAGGA AAAATCGAGGAATAA CTCCTAAAGGTGGTG GTtctaaaggtgaagaattatt	1C, 7C-D	Isolate GFP tagging cassette from p11 with flanking integration sequences for Hda3; long oligo
ABo_461	R2HDA3_GFP	CTTATCATTTACATAA TTAAAAAACAAAAA ACAAGCTAATCTTAT GTTTATGTGGGGGCC ACATTTTCTgaattccgg aatatttatgagaaac	1C, 7C-D	Isolate GFP tagging cassette from p11 with flanking integration sequences for Hda3; long oligo
ABo_145	PF1_his1	GTTCCAGCAGATGGC	1C, 7C-D	Check Hda3-GFP or

		GAGTAC		Hda2-GFP tagging
ABo_261	Pr4_hda2chk_rev	GTAATATCTGATCAG AACCTTT	1C, 7C-D	Check Hda2-GFP tagging
ABo_262	Pr4_hda3chk_rev	TCGTTAATCAAAATTA TACACTC	1C, 7C-D	Check Hda3-GFP tagging
ABo_229	HDA2D_Clox_Fw1	TCTATTTTCAAGAAGT TAGACCCATTCTTGG AATAATTATACTTGCA AGAGAAGGCATTGAA ATTGCATTACGGCCA GTGAATTGTAATA	1D	Isolate deletion cassette from p80 or p83 with flanking integration sequences for Hda2; long oligo
ABo_230	HDA2D_Clox_rev1	GCATGTATTTACAAA TTTTTGGATAAGAAA AAGTAGCATATGGAA ACACAAAACCAAGAA AGAAATCATGTCTGGA ATTAACCCTCACTAA	1D	Isolate deletion cassette from p80 or p83 with flanking integration sequences for Hda2; long oligo
ABo_165	Pr1_chck_arg4	AGTGTGGAAAGAAGA GATGC	1D	Check presence of p80 cassette in Hda2 or Hda3 heterozygote
ABo_423	HDA3_Natcloxchk	CCGGTGCTATGGTTA GATTG	1D	Check presence of p83 cassette in hda2ΔΔ or hda3ΔΔ
ABo_261	Pr4_hda2chk_rev	GTAATATCTGATCAG AACCTTT	1D	Check presence of p80 cassette in Hda2 heterozygote and hda2ΔΔ
ABo_413	HDA2chk_internalfw	CAGCAGGTAGACTTG ATG	1D	Check presence/absence of Hda2 in hda2ΔΔ unresolved/resolved
ABo_261	Pr4_hda2chk_rev	GTAATATCTGATCAG AACCTTT	1D	Check presence/absence of Hda2 in hda2ΔΔ unresolved/resolved
ABo_231	HDA3D_Clox_Fw1	GTTCTTAATATTTGTA ACTTTTCCAACCTTAAA ATAATTATTGCATATT GCACTAAACTAAAA CTACTATAAATacggcc agtgaattgtaata	1D	Isolate deletion cassette from p80 or p83 with flanking integration sequences for Hda3; long oligo
ABo_232	HDA3D_Clox_Rev1	CAATCTTATCATTTAC ATAATTAAAAAACAA AAAACAAGCTAATCT TATGTTTATGTGGGG GCCACATTTTCTtcgga attaaccctcactaa	1D	Isolate deletion cassette from p80 or p83 with flanking integration sequences for Hda3; long oligo
ABo_262	Pr4_hda3chk_rev	TCGTTAATCAAAATTA TACACTC	1D	Check presence of p80 or p83 cassette in Hda3 heterozygote or hda3ΔΔ
ABo_415	HDA3chk_internalfw	CAACAAGAAcTGTGG AACATG	1D	Check presence/absence of Hda3 in hda3ΔΔ

				unresolved/resolved
ABo_416	HDA3chk_internalrev	GGTGGTTCTATAAAT CCCGG	1D	Check presence/absence of Hda3 in hda3ΔΔ unresolved/resolved
ABo_462	Pf_MTLα1_Chk	TTGAAGCGTGAGAG GCAGGAG	4D	Check presence of MATα
ABo_463	Pr_MTLα1_Chk	GTTTGGGTTCTTCT TTCTCATTC	4D	Check presence of MATα
ABo_464	Pf_MTLα1_Chk	TTCGAGTACATTCTG GTCGCG	4D	Check presence of MATα
ABo_465	Pr_MTLα1_Chk	TGTAAACATCCTCAA TTGTACCCGA	4D	Check presence of MATα
ABo_511	Pf_SAT1	GGTGGCGGAAACATT GGATG	4D	Check presence of Sat1
ABo_512	Pr_SAT1	TCAATGCCGCCGAGA GTAAA	4D	Check presence of Sat1
ABo_624	HDA3_XhoI_fw	TAAGCACTCGAGATG gatttaaggaaaatttg	6C	Isolate Hda3 from ABp152 with XhoI and BglII sites (for cloning into ABp111)
ABo_625	HDA3_stpBglII_rv	TTAACGAGATCTtatttta ggagtattcctcgat	6C	Isolate Hda3 from ABp152 with XhoI and BglII sites (for cloning into ABp111: pNIM)
ABo_416	HDA3chk_internalrev	GGTGGTTCTATAAAT CCCGG	6C	Confirm cloning of p177 (Hda3_pNIM)
ABo_514	pNIM_Rev2	CAGTTTGGTTCAGCA CCTTG	6C	Confirm cloning of ABp_177 (Hda3_pNIM)
LD_515		CCATCATAAAATGTC GAGCGTC	6C	Sequencing of ABp_177 (Hda3_pNIM)
ABo_350	Pf_sir2_adh1	ctctatcactgataggagtg	6C	Confirm reintegration of ABp_177 (Hda3_pNIM) cassette at ADH1 locus
ABo_174	Act1_Fw2	CTACGTTTCCATTCA AGCTGTT	5D	qRT-PCR for ACT1
ABo_176	Act1_Rev3	AAACTGTAACACGT TCAGACA	5D	qRT-PCR for ACT1
ABo_469	qALS3_Fw1	CCTATTCCAACAAC ACAAT	5D	qRT-PCR for ALS3
ABo_470	qALS3_Rev1	TATTGAGTCAGTTGG ATTAG	5D	qRT-PCR for ALS3
ABo_471	qHWP1_Fw1	CCAGTTACTTCTGGA TCATC	5D	qRT-PCR for HWP1
ABo_472	qHWP1_Rev1	TCGGTACAAACACTG TTAGA	5D	qRT-PCR for HWP1

848

849

850 **Table 3.** Plasmids used in this study.

ABp_Number	Plasmid	Figure	Description/Source	Source
ABp_11	pGFP-His1	1C	GFP tagging vector	(45)
ABp_17	pHA_NAT1	1C	HA tagging vector	(43)
ABp_80	LAL (loxP-ARG4-loxP)	1D	<i>Arg4</i> substitution products	(33)
ABp_83	NAT1-Clox (loxP-NAT1-MET3p-cre-loxP)	1D	<i>Nat</i> substitution products	(33)
ABp_88	HDA1_synthetic	1C	Hda1 synthetic	GeneArt
ABp_111	pNIM	6C	Tetracycline inducible integration to ADH1 locus	(44)
ABp_133	HDA1synthetic_pHA_NAT	1C	Source of Hda1-HA integration cassette	This study
ABp_136	Sat1 flipper with MTL α KO flanking regions	4D	Deletion of MAT α	Gift from Matthew Anderson Lab, Ohio State
ABp_152	HDA3 synthetic	6C	HA-HDA3 synthetic: 6x CUG->TCA	GeneArt
ABp_177	HDA3-pNIM	6C	Tetracycline inducible integration of Hda3 to ADH1 locus	This study

851

A

B

A **B** **C**

WOR1 (C1_10150W)

Strain	Log2 Fold change	p	q
<i>hda1</i> Δ/Δ	3.95	3.86 e-32	5.92 e-29
<i>hda2</i> Δ/Δ	2.46	4.61 e-13	2.67 e-10
<i>hda3</i> Δ/Δ	2.50	1.46 e-13	2.62 e-10

D

A

WT YPD vs RPMI

B

HYPHAE MEDIUM

C

D

A

B

C

D